ANNX's three largest insider shareholders as of August 29, 2026 are Muneer A Satter (Director, 10.34Mn shares), Capital Life Sciences Investors, Llc Bain (TenPercentOwner, 5.70Mn shares), Capital Life Sciences Investors, Llc Bain (TenPercentOwner, 5.70Mn shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Muneer A Satter | Director | 0 | 10,342,134 | 10,342,134 | 60.2% | 29 May, 2026 |
| 2 | Capital Life Sciences Investors, Llc Bain | TenPercentOwner | 0 | 5,701,926 | 5,701,926 | 33.2% | 30 May, 2023 |
| 3 | Douglas Love | President And Ceo | 351,554 | 0 | 351,554 | 2.0% | 18 Feb, 2025 |
| 4 | Ted Yednock | Evp Chief Innovation Officer | 184,807 | 0 | 184,807 | 1.1% | 15 Jun, 2026 |
| 5 | Michael Overdorf | Evp Chief Business Officer | 182,625 | 0 | 182,625 | 1.1% | 04 Mar, 2026 |
| 6 | Dean Richard Artis | Evp Chief Scientific Officer | 180,093 | 0 | 180,093 | 1.0% | 04 Mar, 2026 |
| 7 | Jamie Dananberg | Chief Medical Officer | 123,582 | 0 | 123,582 | 0.7% | 04 Mar, 2026 |
| 8 | William H. Carson | Director | 70,405 | 0 | 70,405 | 0.4% | 14 Apr, 2026 |
| 9 | Jung Choi | Director | 0 | 33,000 | 33,000 | 0.2% | 03 Dec, 2025 |
| 10 | Larry Mattheakis | Evp Chief Scientific Officer | 17,188 | 0 | 17,188 | 0.1% | 13 Jul, 2022 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 10 Aug, 2026 | Mark S. Blumenkranz | Director | Acquired A | 175,000 | $0.00 | $0 | 175,000 | Direct |
| 11 Jun, 2026 | William A Jr Jones | Director | Acquired A | 65,000 | $0.00 | $0 | 65,000 | Direct |
| 11 Jun, 2026 | Muneer A Satter | Director | Acquired A | 65,000 | $0.00 | $0 | 65,000 | Direct |
| 11 Jun, 2026 | Jung Choi | Director | Acquired A | 65,000 | $0.00 | $0 | 65,000 | Direct |
| 11 Jun, 2026 | Bettina M. Cockroft | Director | Acquired A | 65,000 | $0.00 | $0 | 65,000 | Direct |
| 11 Jun, 2026 | Ted Yednock | Evp Chief Innovation Officer | Acquired M | 30,646 | $1.85 | $56.70K | 184,807 | Direct |
| 11 Jun, 2026 | Ted Yednock | Evp Chief Innovation Officer | Disposed M | 30,646 | $0.00 | $0 | 0 | Direct |
| 28 May, 2026 | Muneer A Satter | Director | Acquired P | 613,497 | $5.41 | $3.32Mn | 10,342,134 | Indirect |
| 10 Apr, 2026 | William H. Carson | Director | Acquired P | 8,000 | $6.20 | $49.60K | 70,405 | Direct |
| 02 Mar, 2026 | Dean Richard Artis | Evp Chief Scientific Officer | Disposed S | 5,894 | $5.43 | $32.00K | 180,093 | Direct |
| 02 Mar, 2026 | Michael Overdorf | Evp Chief Business Officer | Disposed S | 4,339 | $5.42 | $23.52K | 182,625 | Direct |
| 02 Mar, 2026 | Michael Overdorf | Evp Chief Business Officer | Disposed S | 4,339 | $5.42 | $23.52K | 182,625 | Direct |
| 02 Mar, 2026 | Michael Overdorf | Evp Chief Business Officer | Disposed S | 4,339 | $5.42 | $23.52K | 182,625 | Direct |
| 02 Mar, 2026 | Jamie Dananberg | Chief Medical Officer | Disposed S | 5,820 | $5.43 | $31.60K | 123,582 | Direct |
| 02 Mar, 2026 | Jamie Dananberg | Chief Medical Officer | Disposed S | 5,820 | $5.43 | $31.60K | 123,582 | Direct |
| 02 Mar, 2026 | Michael Overdorf | Evp Chief Business Officer | Disposed S | 4,339 | $5.42 | $23.52K | 182,625 | Direct |
| 02 Mar, 2026 | Michael Overdorf | Evp Chief Business Officer | Disposed S | 4,339 | $5.42 | $23.52K | 182,625 | Direct |
| 19 Feb, 2026 | Douglas Love | President And Ceo | Acquired A | 1,250,000 | $0.00 | $0 | 1,250,000 | Direct |
| 19 Feb, 2026 | Jamie Dananberg | Chief Medical Officer | Acquired A | 56,250 | $0.00 | $0 | 129,402 | Direct |
| 19 Feb, 2026 | Douglas Love | President And Ceo | Acquired A | 1,250,000 | $0.00 | $0 | 1,250,000 | Direct |